The Department of Clinical Pharmacology was the first in Uzbekistan to be established in 1982 by Professor K.N. Najimutdinov at the Tashkent State Medical Institute. Associate professors N.G. Babaeva, R.I. Usmonov, P.S. Kats worked in the department. In 1990, in connection with the establishment of II ToshMI, the department was headed by professor R.I. Usmanov, associate professors A.V. Yakubov, E.B. Zueva. Since 1990, professor I.R. Mavlyanov has headed the department of clinical pharmacology of Tashkent State Medical Institute. Associate professors P.S. Kats, Sh.M. Muzrabekov, L.T. Daminova, R.K. Makhkamova worked in the department under his leadership.
In 2005, in connection with the establishment of the Tashkent Medical Academy, the departments of clinical pharmacology of both institutes were united under the leadership of Professor A. V. Yakubov.
The Department of Clinical Pharmacology at the Samarkand Medical Institute named after Academician I.P. Pavlov was established in 1985 under the leadership of Professor D.N. Ibadova, associate professor, later doctor of medical sciences.
From December 1, 2013 to August 2017, Candidate of Medical Sciences, Associate Professor Ziyadullaev Sh.Kh., Department of Internal Medicine, Pharmacology and Clinical Pharmacology.
From September 2017 to August 2020, Candidate of Medical Sciences, Associate Professor Yoldoshev S.Z., Department of Pharmacology and Clinical Pharmacology.,
From September 2020, I.R. Abdurakhmanov became the head of the Department of Clinical Pharmacology.
At the department, students of the 5th year of "treatment and medical pedagogy" of the subject "Clinical pharmacology", 6th year of pediatrics, 4th year of the faculty of dentistry, 2nd year of higher nursing work, 2nd year of masters of various specialties, as well as 1st year of clinical residency residents is being taught. The main task of the department of clinical pharmacology is to prepare students who have modern clinical and pharmacological knowledge, who can interpret the results of clinical studies of drugs, who can use evidence-based medical information, take into account joint diseases, physiological diseases.
